Details for New Drug Application (NDA): 207967

✉ Email this page to a colleague

NDA 207967 describes MAGNESIUM SULFATE, which is a drug marketed by B Braun Medical, Aspiro, Exela Pharma, Fresenius Kabi Usa, Hospira, Baxter Hlthcare Corp, Hq Spclt Pharma, Pharmobedient, Amneal, Gland, Milla Pharms, and Mylan Labs Ltd, and is included in twenty NDAs. It is available from ten suppliers. Additional details are available on the MAGNESIUM SULFATE profile page.

The generic ingredient in MAGNESIUM SULFATE is magnesium sulfate. There are one hundred and forty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the magnesium sulfate profile page.

Mechanism of Action	Magnesium Ion Exchange Activity Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Inhibition Small Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
MAGNESIUM SULFATE	magnesium sulfate	INJECTABLE;INJECTION	207967	ANDA	B. Braun Medical Inc.	0264-4204	0264-4204-52	24 CONTAINER in 1 CASE (0264-4204-52) / 50 mL in 1 CONTAINER
MAGNESIUM SULFATE	magnesium sulfate	INJECTABLE;INJECTION	207967	ANDA	B. Braun Medical Inc.	0264-4205	0264-4205-52	24 CONTAINER in 1 CASE (0264-4205-52) / 50 mL in 1 CONTAINER

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	2GM/50ML (40MG/ML)
Approval Date:	Apr 26, 2021	TE:	AP	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	4GM/100ML (40MG/ML)
Approval Date:	Apr 26, 2021	TE:	AP	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	4GM/50ML (80MG/ML)
Approval Date:	Apr 26, 2021	TE:	AP	RLD:	No

Complete Access Available with Subscription